This program brings together clinicians, scientists, entrepreneurs, and investors to understand what mental health care can and should look like in the next 2 decades.
Available Credits: 0.00 Participation Register For This CourseOver the last few years, the field of mental health has garnered the most investments relative to other clinical areas. This program brings together clinicians, scientists, entrepreneurs, and investors to understand what mental health care can and should look like in the next 2 decades. By all accounts, current systems of care do not serve patients and their families well: care is hard to access, inefficient and costly, and sometimes unable to restore function and quality of life. At the same time, from neuroimaging to artificial intelligence to mobile apps, we are bombarded with excitement about the future might bring. How do we get past the hype to envision better care? A key first step is understanding what the future could look like, and what would need to happen to make it a reality.
Physicians, Psychologists, and Doctoral-level Professionals: $795.00
Other Professionals: $695.00
Students: Free
Residents & Fellows: Free
Physicians, Psychologists, and Doctoral-level Professionals: $695.00
Other Professionals: $595.00
Students: Free
Residents & Fellows: Free
This two-day conference is intended for clinicians, scientists, entrepreneurs, students, payers and investors with an interest in the future of mental health care
Future of Mental Health Conference
September 16 - 17, 2022
Westin Copley – Boston, MA
Day 1 – September 16, 2022
7:30 AM Continental Breakfast and Registration
8:30 AM -8:35 AM Welcome & Keynote Introduction
David Mou, MD; Roy Perlis, MD
8:35 AM - 9:00 AM Keynote Speaker: Thomas R. Insel, MD
Healing: Our Path from Mental Illness to Mental Health
9:00 AM - 10:30 AM The Future of CNS Drug Development Panel Discussion
Moderator: Roy Perlis, MD
Panelists: Steve M. Paul, MD, Amit Etkin, MD, PhD, Errol DeSouza, PhD, John Dunlop, PhD
10:30 AM - 10:45 AM Coffee Break
10:45 AM 12:15 PM The Promise and Perils of Psychedelics Panel Discussion
Moderator: Jerrold Rosenbaum, MD
Panelists: George J. Goldsmith, Mark Rus, Cristina Cusin, MD, Aidan Hampson, PhD
12:15 PM - 1:30 PM Lunch Break (On you own)
1:30 - 3:00 PM How Telehealth is Transforming Mental Health Delivery Panel Discussion
Moderator: David Mou, MD
Panelists: Stephen Smith, Andrew Welchman, PhD, Anthony Sossong, MD, Seth Feuerstein, MD, JD
3:00 PM - 3:15 PM Coffee Break
3:15 PM - 4:45 PM The Future of Digital Therapeutics Panel Discussion
Moderator: Sabine Wilhelm, PhD
Panelists: Corey McCann, MD, PhD, Eddie Martucci, PhD, Peter Hames, Emily Lattie, PhD, Faith Gunning, PhD
4:45 PM Adjourn
Day 2 – September 17, 2022
7:30 AM Continental Breakfast and Registration
8:30 AM - 8:35 AM Introduction
David Mou, MD; Roy Perlis, MD
8:35 AM - 9:00 AM Keynote Speaker: Maurizio Fava, MD
9:00 AM - 10:30 AM Where is Mental Health Headed? Perspectives from Investors Panel Discussion
Moderator: David Mou, MD
Panelists: Roger Kitterman, MBA, Alexandra Cantley, Solome Tibebu
10:30 AM - 10:45 AM Coffee Break
10:45 AM – 11:10 AM Keynote Speaker: Jim Yong Kim, MD, PhD
Building the Movement for Mental Health Treatment Access: Lessons from Four Decades of Global Health Activism
11:10 AM - 12:30 PM Rethinking Access and Quality in Behavioral Health: Perspectives from Payers Panel Discussion
Moderator: John Herman, MD
Panelists: Neil Leibowitz, MD, JD, Doug Nemecek, MD, MBA, Giuseppe Raviola, MD, MPH
12:30 PM - 1:30 PM Lunch Break (On your own)
1:30 PM - 3:00 PM Leveraging Data Science to Improve Mental Health
Moderator. Roy Perlis, MD
Panelists: Marzyeh Ghassemi, PhD, Zayed Yasin, MD, MBA, Carl D. Marci, MD, Andy Keller, PhD, Christopher Palmer, MD
3:00 PM Closing Remarks
3:05 PM Adjourn
Roy H. Perlis, MD, MSc
Professor of Psychiatry, HMS
Director, Center for Experimental Drugs and Diagnostics, MGH
David Mou, MD, MBA
Director, MGH Psychiatry’s Innovation Council
Chief Executive Officer, Cerebral
SPEAKERS |
| Alexandra Cantley, PhD Partner Polaris Partners |
| Cristina Cusin, MD Director, Ketamine Clinic and Associate Director, Depression Clinical and Research Program Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School |
| Dr. Errol B. De Souza Executive Chairman Bionomics Ltd. |
| John Dunlop, PhD Head of Research and Development Neumora Therapeutics |
| Amit Etkin Founder and CEO Alto Neuroscience |
| Seth D. Feuerstein, MD, JD Faculty, Yale School of Medicine Founder and CEO, Oui Therapeutics Founder, Board Chair, Vytyl Health Senior Advisor, Athyrium Capital HQE, Department of Defense |
Marzyeh Ghassemi, PhD |
| George J. Goldsmith Chairman, CEO and Co-Founder, COMPASS Pathways PLC |
| Faith Gunning, Ph.D. Associate Professor of Psychology in Psychiatry Director of the Weill Cornell Institute of Geriatric Psychiatry Vice Chair for Research Department of Psychiatry |
| Peter Hames Co-Founder and President Big Health |
| Andy Keller, PhD President and CEO Linda Perryman Evans Presidential Chair Meadows Mental Health Policy Institute |
| Roger Kitterman Vice President Mass General Brigham Ventures |
Emily Lattie, PhD |
| Neil Leibowitz, MD, JD CMO Beacon Health Options |
| Carl D. Marci, MD Assistant Professor of Psychiatry, Harvard Medical School (part-time) Staff Clinician, MGH Revere Mental Health Center (part-time) Chief Psychiatrist and Managing Director, Mental Health and Neuroscience, OM1, Inc. |
| W. Eddie Martucci, PhD CEO and Co-Founder, Akili |
| Corey M. McCann, MD, PhD President and CEO, Pear Therapeutics, Inc |
| Doug Nemecek, MD, MBA Chief Medical Officer Evernorth Behavioral Health |
| Christopher M. Palmer, MD Director, Dept. of Postgraduate and Continuing Education, McLean Hospital Assistant Professor of Psychiatry, Harvard Medical School |
| Steven M. Paul, MD CEO and Chairman Karuna Therapeutics Professor of Psychiatry and Neurology Washington University School of Medicine |
| Guiseppe Raviola, MD, MPH Massachusetts General Hospital Department of Psychiatry Associate Director, The Chester M. Pierce, MD Global Psychiatry Division Assistant Professor of Psychiatry Division of Child and Adolescent Psychiatry Harvard Medical School Department of Global Health and Social Medicine Director, The Program in Global Mental Health and Social Change Assistant Professor in Global Health and Social Medicine |
| Jerrold Rosenbaum, MD Psychiatrist-in-Chief, Emeritus Director, Center for the Neuroscience of Psychedelics Massachusetts General Hospital Stanley Cobb Professor of Psychiatry Harvard Medical School |
| Mark Rus Chief Executive Officer Delix Therapeutics |
| Stephen Smith Cofounder and CEO of NOCD |
Anthony Sossong, MD |
Andrew Welchman, PhD |
Sabine Wilhelm, PhD |
| Zayed Yasin, MD, MBA SVP, Clinical Firsthand |
This course allows other providers to claim a Participation Certificate upon successful completion of this course.
Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1 Credit™ associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMA PRA Category 1 Credit™ may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.